VacV was awarded Innovate UK Grant on 10/09/2024: “Transforming Cancer Therapeutics: Preclinical development of a systemically deliverable oncolytic Vaccinia Virus for treatment of metastatic colorectal cancer” Metastatic (stage 4) colorectal cancer (mCRC) is an almost uniformly lethal disease with only a 14% 5-year survival rate. Current treatment strategies for mCRC are limited and escape form […]

VacV Biotherapeutics (“VacV” or “the Company”), a cancer immunotherapy company developing innovative viral-based therapies, emerged from stealth mode today to advance its promising pipeline of pre-clinical assets with best-in-class potential, towards the clinic.